Lilic V, Lilic G, Filipovic S, Milosevic J, Tasic M, Stojiljkovic M
Clinic of Gynecology and Obstetrics, Clinical Centre Nis, Nis, Serbia.
J BUON. 2009 Oct-Dec;14(4):587-92.
Treatment of invasive cervical carcinoma is determined by the clinical disease stage. Microinvasive carcinoma of the uterine cervix, due to its limited metastatic potential, is usually curable with non-radical treatment. There are no standard approaches to the treatment of stage Ib-IIa carcinoma of the uterine cervix. Both radical surgery and radical radiotherapy are utilized with similar efficacy but with different associated morbidity and complications. Stage Ib1 was commonly treated with radical hysterectomy plus pelvic lymphadenectomy. Laparoscopically-assisted radical vaginal hysterectomy demonstrated similar efficacy and recurrence rates for this disease stage. In cases where fertility is to be preserved, radical vaginal trachelectomy is a valid option for small cervical cancers. Among the papers dealing with bulky cervical disease (stages Ib-IIa) a great deal of disagreement is evident. Some oncologic centres prefer primary surgery with postoperative radiotherapy, with or without chemotherapy, while others prefer primary chemoradiotherapy. Moreover, as a possible alternative, neoadjuvant chemotherapy followed by radical surgery is recommended for stage Ib2 disease. Simultaneous chemoradiation is being introduced as a new standard for advanced cancer, since it has been clearly demonstrated that it can prolong disease-free and overall survival. The treatment of recurrent carcinoma depends on the type of previous treatment, site and extent of recurrent disease, and on the disease-free period and general health of the patient. In conclusion, the decision on the treatment approach for invasive carcinoma of the uterine cervix should be individualized, based on numerous factors, such as disease stage, general health of the patient, cancer-related factors, in order to choose the best approach with minimal complications.
浸润性宫颈癌的治疗取决于临床疾病分期。子宫颈微浸润癌由于其转移潜能有限,通常采用非根治性治疗即可治愈。子宫颈Ib-IIa期癌的治疗尚无标准方法。根治性手术和根治性放疗均有应用,疗效相似,但相关的发病率和并发症不同。Ib1期通常采用根治性子宫切除术加盆腔淋巴结清扫术治疗。腹腔镜辅助根治性阴道子宫切除术对该疾病分期显示出相似的疗效和复发率。对于希望保留生育功能的患者,根治性阴道宫颈切除术是治疗小型宫颈癌的有效选择。在处理体积较大的宫颈癌(Ib-IIa期)的文献中,明显存在很大分歧。一些肿瘤中心倾向于采用术后放疗的一期手术,可联合或不联合化疗,而其他中心则倾向于一期放化疗。此外,作为一种可能的替代方案,对于Ib2期疾病,建议先行新辅助化疗,然后进行根治性手术。同步放化疗正被引入作为晚期癌症的新标准,因为已经明确证明它可以延长无病生存期和总生存期。复发性癌的治疗取决于先前的治疗类型、复发性疾病的部位和范围,以及患者的无病期和总体健康状况。总之,子宫颈浸润癌治疗方法的决策应个体化,基于多种因素,如疾病分期、患者总体健康状况、癌症相关因素等,以便选择并发症最少的最佳方法。